

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 October 2006 (26.10.2006)

PCT

(10) International Publication Number
WO 2006/113917 A1

(51) International Patent Classification:
C07C 69/76 (2006.01)

(21) International Application Number:
PCT/US2006/015163

(22) International Filing Date: 20 April 2006 (20.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/673,655 20 April 2005 (20.04.2005) US

(71) Applicant (for all designated States except US):
METABOLEX, INC. [US/US]; 3876 Bay Center
Place, Hayward, California 94545 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAUGS, Edward, D.** [US/US]; 2788 Tupelo, Midland, Michigan 48642 (US). **HAGEN, Eric, J.** [US/US]; 1123 Trillium Lane, Lafayette, Indiana 47905 (US). **HANKO, Jason, A.** [US/US]; 4301 Antiquity Court, West Lafayette, Indiana 47906 (US). **LOUKS, David, H.** [US/US]; 8466 Circlewood Drive North, Saginaw, Michigan 48609 (US).

(74) Agents: **HOPKINS, Mark, H.** et al.; Townsend And Townsend And Crew Llp, Two Embarcadero Center, 8th Floor, San Francisco, California 94111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: CRYSTALLINE SOLID AND AMORPHOUS FORMS OF (-)- HALOFENATE



(57) Abstract: The present invention provides crystalline solid and amorphous forms of (-)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (-)-halofenate.

WO 2006/113917 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.